APOB and inflammatory bowel disease: While Fusicatenibacter saccharivorans shows promise in treating inflammatory bowel disease, in our study, Fusicatenibacter saccharivorans (r = 0.4, p = 0.006) exhibited a significant positive correlation with ApoB.